Jubilant Ingrevia Limited has confirmed the successful completion of the acquisition of 100% equity stake in Remidex Pharma Private Limited. This final step follows the initial Share Purchase Agreement intimated on March 13, 2026. The key terms of the transaction were previously disclosed to the Stock Exchanges. The official event confirming the closure of the deal occurred on March 30, 2026, at 6:05 PM (IST).
Completion of Strategic Acquisition
Jubilant Ingrevia Limited is pleased to announce the successful closing of its planned strategic investment. This update confirms that the Company has now acquired the 100% equity stake in Remidex Pharma Private Limited, referred to as ‘Remidex’.
This action finalizes the agreement established through the Share Purchase Agreement previously disclosed to the exchanges. The preliminary announcement regarding the agreement was made on March 13, 2026.
Transaction Finalization Details
The Company confirms that the acquisition of the entire stake in Remidex has been completed as per the terms outlined in the earlier intimation. The key commercial terms governing this transaction were duly communicated to the Stock Exchanges on March 13, 2026. The official date and time confirming the occurrence of this event—the final acquisition—was recorded as March 30, 2026, at 6:05 pm(IST).
All necessary details required under the relevant regulations concerning this material transaction were previously disclosed in the intimation dated March 13, 2026.
Source: BSE
